PT - JOURNAL ARTICLE AU - Hok-A-Hin, Yanaika S. AU - Vermunt, Lisa AU - Peeters, Carel F.W. AU - van der Ende, Emma L. AU - de Boer, Sterre C.M. AU - Meeter, Lieke H. AU - van Swieten, John C. AU - Hu, William T. AU - Lleó, Alberto AU - Alcolea, Daniel AU - Engelborghs, Sebastiaan AU - Sieben, Anne AU - Chen-Plotkin, Alice AU - Irwin, David J. AU - van der Flier, Wiesje M. AU - Pijnenburg, Yolande A.L. AU - Teunissen, Charlotte E. AU - del Campo, Marta TI - Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of Frontotemporal Dementia AID - 10.1101/2024.08.19.24312100 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.19.24312100 4099 - http://medrxiv.org/content/early/2024/08/20/2024.08.19.24312100.short 4100 - http://medrxiv.org/content/early/2024/08/20/2024.08.19.24312100.full AB - Diagnosis of Frontotemporal dementia (FTD) and the specific underlying neuropathologies (frontotemporal lobar degeneration; FTLD-Tau and FTLD-TDP) is challenging, and thus fluid biomarkers are needed to improve diagnostic accuracy. We used proximity extension assays to analyze 665 proteins in cerebrospinal fluid (CSF) samples from a multicenter cohort including patients with FTD (n = 189), Alzheimer’s Disease dementia (AD; n = 232), and cognitively unimpaired individuals (n = 196). In a subset, FTLD neuropathology was determined based on phenotype or genotype (FTLD-Tau = 87 and FTLD-TDP = 68). Forty three proteins were differentially regulated in FTD compared to controls and AD, reflecting axon development, regulation of synapse assembly, and cell-cell adhesion mediator activity pathways. Classification analysis identified a 14- and 13-CSF protein panel that discriminated FTD from controls (AUC: 0.96) or AD (AUC: 0.91). Custom multiplex panels confirmed the highly accurate discrimination between FTD and controls (AUCs > 0.96) or AD (AUCs > 0.88) in three validation cohorts, including one with autopsy confirmation (AUCs > 0.90). Six proteins were differentially regulated between FTLD-TDP and FTLD-Tau, but no reproducible classification model could be generated (AUC: 0.80). Overall, this study introduces novel FTD-specific biomarker panels with potential use in diagnostic setting.Competing Interest StatementY.H., C.P., E.E., S.B., L.M, J.S., W.H., A.S., A.C.-P, and D.I. declare no competing interest. M.C. has been an invited speaker at Eisai, is an associate editor at Alzheimers Research & Therapy and has been an invited writer for Springer Healthcare. L.V. received a grant for CORAL consortium by Olink proteomics. D.I. is a Scientific Advisory Board Member for Denali Therapeutics. D.A. participated in advisory boards from Fujirebio-Europe and Roche Diagnostics and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmaceutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals. S.A. D.A., and A.L. declare a filed patent application (Title: Markers of synaptopathy in neurodegenerative disease; Applicant: Fundacio Institut de Recerca de Hospital de la Santa Creu i Sant Pau, Inventors: Olivia BELBIN; Alberto LLEO; Alejandro BAYES; Juan FORTEA; Daniel ALCOLEA; Application number: PCT/EP2019/056535; International Publication Number: WO 2019/175379 A1; Current status: Active. Licensed to ADx Neurociences NV (Ghent, Belgium); this patent is not related to any specific aspect of the current manuscript). S.E. received personal fees from Eisai (paid to institution), personal fees from icometrix (paid to institution), personal fees from Novartis (paid to institution), personal fees from Roche (paid to institution) and personal fees from Roche and personal fees from Biogen, all outside the submitted work. W.F. has performed contract research for Biogen MA Inc, and Boehringer Ingelheim. W.F. has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), Springer Healthcare. W.F. is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc and Roche. All funding is paid to her institution. W.F. is a member of the steering committee of PAVE, and Think Brain Health. W.F. was associate editor of Alzheimers Research & Therapy in 2020/2021 and is currently an associate editor at Brain. C.E.T. has a collaboration contract with ADx Neurosciences, Quanterix, and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, and Vivoryon. She serves on editorial boards of Medidact Neurologie/Springer, Alzheimers Research & Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer. She had speaker contracts for Roche, Grifols, and Novo Nordisk.Funding StatementThis project was funded by the memorable project PRIDE (Project No. WE.03-2018-05), supported by Alzheimer Nederland. MdC is supported by the attraction talent fellowship from Comunidad de Madrid (2018-T2/BMD-11885). Data from Penn were contributed by the program project grants P01-AG-066597, U19 AG062418 (formerly P50 NS053488), and P30AG072979 (formerly AG010124).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was given by the institutional ethical review boards of each center (Amsterdam UMC: AD CSF biobank METC number 00/211; University of Pennsylvania: language and cognitive impairment in Parkinsons disease and Parkinsons disease with dementia or DLB IRB069801; Emory University: IRB00042049; Erasmus MC: METC numbers 124.378/1993/17 and 202.927/2001/143 or under the Parelsnoer initiative 2009-170; SPIN cohort: COLLECTION 16/2013). All participants gave written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data generated in this study is available from the authors on reasonable request.